ClinicalTrials.gg
CompletedNCT05345223Updated Dec 20, 2024

A Registry Study on Primary/idiopathic Triglyceride Deposit Cardiomyovasculopathy

An observational study in Triglyceride Deposit Cardiomyovasculopathy, sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
193
Ages
20 Years and older
Sex
All
01

Study summary

The objective of this study is to construct a registry; in order to understand the onset status of triglyceride deposit cardiomyovasculopathy (TGCV) in Japan with patients' background and natural history of the disease, and to explore disease-specific prognostic factors.

02

Conditions studied

  • Triglyceride Deposit Cardiomyovasculopathy

Keywords

  • triglyceride deposit cardiomyovasculopathy
  • TGCV
03

In context

Lead sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan is the lead sponsor of 55 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (excluding under 20 years old) who have been confirmed as TGCV based on the diagnostic criteria for TGCV by a cardiologist.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients who have been confirmed as TGCV based on the diagnostic criteria for TGCV

Exclusion criteria

Exclusion Criteria:

  • The patients who refused to participate in the study by opt-out
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
193 participants (actual)
Patient registry
No

Groups and cohorts

  • TGCV

    Patients who have been confirmed as TGCV by a cardiologist.

06

What researchers measure

Primary outcomes

  1. The period between the date of TGCV diagnosis and the date of death due to any cause

    The period is from the date of diagnosis of TGCV to the date of death due to any cause. Survival and lost follow-up cases will be censored on the final confirmation date of survival.

    Time frame: 10 years

Secondary outcomes

  1. Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: Washout rate of BMIPP (%)

    Time frame: 10 years

  2. Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: LVEF (%) (UCG or QGS)

    Time frame: 10 years

  3. Comparison of subjective symptoms, laboratory findings, and event occurrence before and after tricaprin therapy: Any cardiovascular events

    Time frame: 10 years

  4. Presence (date of occurrence or treatment) or absence of various events

    To measure the period from the date of diagnosis of TGCV to the date the following event occurs: non-fatal myocardial infarction by the outcome assessment, non-fatal stroke, hospitalization for heart failure, CABG, PCI, TVR, pacemaker/ICD implantation, CRT, VAD, acute coronary syndrome requiring hospitalization, hospitalization/device activation/heart transplantation due to fatal arrhythmia. However, surgery scheduled at the time of diagnosis will not be treated as an event.

    Time frame: 10 years

07

Study locations

7 sites
  • Aichi Medical University
    Nagakute, Aichi 4801195, Japan
  • Nagoya University
    Nagoya, Aichi 4668560, Japan
  • Hyogo Medical University
    Nishinomiya, Hyogo 6638501, Japan
  • Osaka University Hospital
    Suita, Osaka 5650871, Japan
  • Juntendo University
    Bunkyo, Tokyo 1138431, Japan
  • Chiba University Graduate School of Medicine
    Chiba, 2608677, Japan
  • Kyushu University
    Fukuoka, 8128582, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Dec 2023, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2022
First posted
Apr 25, 2022
StartActual
Mar 31, 2022
Primary completionActual
Dec 31, 2023
CompletionActual
Dec 31, 2023
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05345223
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborators
Osaka University Graduate School of Medicine
Responsible party
Sponsor
First posted
Apr 25, 2022
Start date
Mar 31, 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Last update
Dec 20, 2024

Study contacts

Ken-ichi Hirano, MD, PhD
principal investigator · Department of Triglyceride Science, Graduate School of Medicine, Osaka University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion